UNCY Stock Analysis: Buy, Sell, or Hold?
UNCY - Unicycive Therapeutics, Inc. Common Stock
$8.00
-0.02 (-0.25%)
▼
5d:
+11.58%
30d:
-0.99%
90d:
+25.2%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When UNCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: UNCY shows positive signals but monitor for confirmation. Market pricing in 7.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: UNCY shows positive signals but monitor for confirmation. Market pricing in 7.8% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.31
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.78
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UNCY is currently trading at $8.00, which is considered extended relative to its 30-day fair value range of $7.01 to $7.82. From a valuation perspective, the stock is trading at a premium (Forward PE: 1.3) compared to its historical average (1.1). At these levels, the market is pricing in 7.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UNCY is in a uptrend. The price is approaching resistance at $8.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: UNCY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $41.30 (+415.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, UNCY is in a uptrend. The price is approaching resistance at $8.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: UNCY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $41.30 (+415.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.01 -
$7.82
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.0%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 415.0% below Wall St target ($41.30)
- NEUTRAL: Trading at premium valuation - market expects 7.8% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$7.01 -
$7.82
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.65
Resistance Level
$8.02
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.33
Wall Street Target
$41.30
(+415.0%)
Valuation Premium vs History
+7.8% premium
PE vs Historical
1.3 vs 1.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.8%
(market-implied from PE analysis)
1-Year Target
$8.65
(+8%)
2-Year Target
$9.32
(+16%)
3-Year Target
$10.05
(+25%)
3-Yr Target (if PE normalizes)
(PE: 1→1)
PE COMPRESSION
$8.32
(+4%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 24, 2026 2:32 PM ET
Data refreshes hourly during market hours. Next update: 3:32 PM
Data refreshes hourly during market hours. Next update: 3:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UNCY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 58 HOLD |
